MNG497
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.586
- MYC_TARGETS_V2+0.561
- G2M_CHECKPOINT+0.491
- MYC_TARGETS_V1+0.484
- CHOLESTEROL_HOMEOSTASIS+0.219
- DNA_REPAIR+0.197
- MTORC1_SIGNALING+0.178
- UNFOLDED_PROTEIN_RESPONSE+0.156
- MITOTIC_SPINDLE+0.132
- WNT_BETA_CATENIN_SIGNALING+0.097
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.434
- INTERFERON_ALPHA_RESPONSE-0.412
- APICAL_SURFACE-0.405
- INTERFERON_GAMMA_RESPONSE-0.396
- ALLOGRAFT_REJECTION-0.393
- INFLAMMATORY_RESPONSE-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.375
- UV_RESPONSE_DN-0.375
- KRAS_SIGNALING_UP-0.339
- TGF_BETA_SIGNALING-0.319
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598228 | fetal | fetal | 0.889 |
| 2 | MNG473 | — | — | 0.885 |
| 3 | BS_R439VVPK | medulloblastoma | — | 0.882 |
| 4 | BS_HE57E1RP | medulloblastoma | — | 0.880 |
| 5 | BS_FKDQJJB5 | medulloblastoma | — | 0.878 |
| 6 | BS_W644VEVE | medulloblastoma | — | 0.876 |
| 7 | TCGA-WA-A7GZ-01A-11R-A34R-07 | — | — | 0.873 |
| 8 | 085e4228-8ed7-44d7-9ab5-8a096434b650 | — | — | 0.870 |
| 9 | BS_JZRM1S3T | medulloblastoma | — | 0.867 |
| 10 | BS_2Z1MKS84 | medulloblastoma | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.586 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.561 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.491 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.484 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.219 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.197 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.178 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.156 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.132 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.097 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.093 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.084 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.068 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.037 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.031 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |